{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:39:51Z","timestamp":1759412391199},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>In France, about 30% of the population refuses COVID-19 vaccination outright, and 9 to 40% are hesitant. We developed and evaluated an interactive web tool providing transparent and reliable information on the benefits and risks of COVID-19 vaccination.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The most recent scientific data at the time of the study were implemented into an interactive web tool offering individualized information on the risks of COVID-19 infection-related events versus vaccination-related serious adverse events. The tool was evaluated during a before-and-after impact study nested in ComPaRe, a French e-cohort of adult patients with chronic conditions. Primary outcome was the proportion of patients intending to receive vaccination after using the tool, among those not intending to receive it at baseline.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between January 8 and 14, 2021, we enrolled 3152 patients in the study [mean age 55.2 (SD: 16.9), 52.9% women and 63% with \u2265\u20092 chronic conditions]. Before consulting the tool, 961 (30.5%) refused to be vaccinated until further data on efficacy\/safety was obtained and 239 (7.5%) outright refused vaccination. Among these 1200 patients, 96 (8.0%, number needed to treat: 12.5) changed their mind after consulting the tool and would subsequently accept vaccination.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our interactive web tool represents a scalable method to help increase the intent to receive COVID-19 vaccination among patients with chronic conditions and address vaccine hesitancy. Since April 2021, our tool has been embedded on the official webpage of the French Government for COVID-19 information.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12911-021-01594-8","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T11:02:49Z","timestamp":1627729369000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of an interactive web tool on patients\u2019 intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France"],"prefix":"10.1186","volume":"21","author":[{"given":"Viet-Thi","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Sidorkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"P\u00e9an","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"issue":"34","key":"1594_CR1","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","volume":"33","author":"NE MacDonald","year":"2015","unstructured":"MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161\u20134.","journal-title":"Vaccine"},{"key":"1594_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ebiom.2016.08.042","volume":"12","author":"HJ Larson","year":"2016","unstructured":"Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:295\u2013301.","journal-title":"EBioMedicine"},{"key":"1594_CR3","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00012-8","volume":"6","author":"M Schwarzinger","year":"2021","unstructured":"Schwarzinger M, Watson V, Arwidson P, Alla F, Luchini S. COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics. Lancet Public Health. 2021;6:e210\u201321.","journal-title":"Lancet Public Health"},{"key":"1594_CR4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.7326\/M20-3569","volume":"173","author":"KA-O Fisher","year":"2020","unstructured":"Fisher KA-O, Bloomstone SJ, Walder JA-O, Crawford SA-O, Fouayzi HA-O, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. Ann Intern Med. 2020;173:964\u201373 (1539\u20133704 (Electronic)).","journal-title":"Ann Intern Med"},{"key":"1594_CR5","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMe2106315","volume":"384","author":"DB Cines","year":"2021","unstructured":"Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254\u20136.","journal-title":"N Engl J Med"},{"issue":"6500","key":"1594_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.abc3517","volume":"369","author":"H Salje","year":"2020","unstructured":"Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, Andronico A, Hoz\u00e9 N, Richet J, Dubost CL, et al. Estimating the burden of SARS-CoV-2 in France. Science (New York, NY). 2020;369(6500):208\u201311.","journal-title":"Science (New York, NY)"},{"key":"1594_CR7","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"1594_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"1594_CR9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, et al. Attributes and predictors of long COVID. Nature Med. 2021;27:626\u201331.","journal-title":"Nature Med"},{"issue":"33","key":"1594_CR10","doi-asserted-by":"publisher","first-page":"10321","DOI":"10.1073\/pnas.1504019112","volume":"112","author":"Z Horne","year":"2015","unstructured":"Horne Z, Powell D, Hummel JE, Holyoak KJ. Countering antivaccination attitudes. Proc Natl Acad Sci U S A. 2015;112(33):10321\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1594_CR11","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1001\/archinte.167.10.1076","volume":"167","author":"AJ Weymiller","year":"2007","unstructured":"Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christianson TJ, Mullan RJ, Smith SA. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med. 2007;167(10):1076\u201382.","journal-title":"Arch Intern Med"},{"issue":"7565","key":"1594_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/bmj.38926.629329.AE","volume":"333","author":"G Elwyn","year":"2006","unstructured":"Elwyn G, O\u2019Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R, Barratt A, Barry M, Bernstein S, et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ Clin Res Ed. 2006;333(7565):417.","journal-title":"BMJ Clin Res Ed"},{"key":"1594_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jclinepi.2020.04.021","volume":"124","author":"VT Tran","year":"2020","unstructured":"Tran VT, Ravaud P. COllaborative open platform E-cohorts for research acceleration in trials and epidemiology. J Clin Epidemiol. 2020;124:139\u201348.","journal-title":"J Clin Epidemiol"},{"key":"1594_CR14","unstructured":"Direction de la recherche d\u00e9, de l\u2019\u00e9valuation et des statistiques.: L\u2019\u00e9tat de sant\u00e9 de la population en France\u2014RAPPORT 2017. In: Paris: Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9\u2014R\u00e9publique Fran\u00e7aise; 2017."},{"key":"1594_CR15","unstructured":"VaccinTracker: Combien de fran\u00e7ais ont \u00e9t\u00e9 vaccin\u00e9s contre la Covid19? https:\/\/covidtracker.fr\/vaccintracker\/."},{"key":"1594_CR16","unstructured":"Quels sont les b\u00e9n\u00e9fices et risques des vaccins contre la Covid-19? https:\/\/www.gouvernement.fr\/quels-sont-les-benefices-et-risques-des-vaccins-contre-la-covid-19."},{"key":"1594_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2020","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2020;397:99\u2013111.","journal-title":"Lancet (London, England)"},{"key":"1594_CR18","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, C\u00e1rdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384:2187\u2013201.","journal-title":"N Engl J Med"},{"key":"1594_CR19","unstructured":"AstraZeneca\u2019s COVID-19 vaccine: benefits and risks in context. https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-benefits-risks-context."},{"issue":"10","key":"1594_CR20","doi-asserted-by":"publisher","first-page":"e2021726118","DOI":"10.1073\/pnas.2021726118","volume":"118","author":"RM Kaplan","year":"2021","unstructured":"Kaplan RM, Milstein A. Influence of a COVID-19 vaccine\u2019s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci U S A. 2021;118(10):e2021726118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"1594_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1001\/jama.2021.4300","volume":"325","author":"R Wilf-Miron","year":"2021","unstructured":"Wilf-Miron R, Myers V, Saban M. Incentivizing vaccination uptake: the \u201cGreen Pass\u201d proposal in Israel. JAMA. 2021;325(15):1503\u20134.","journal-title":"JAMA"},{"key":"1594_CR22","first-page":"g5074","volume":"349","author":"P Sedgwick","year":"2014","unstructured":"Sedgwick P. Before and after study designs. BMJ Clin Res Ed. 2014;349:g5074.","journal-title":"BMJ Clin Res Ed"},{"key":"1594_CR23","doi-asserted-by":"publisher","unstructured":"Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, Parker MA, Kim RJ. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. 2021. https:\/\/doi.org\/10.1001\/jamacardio.2021.2828.","DOI":"10.1001\/jamacardio.2021.2828"},{"issue":"7","key":"1594_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S1473-3099(20)30426-6","volume":"20","author":"COCONEL Group","year":"2020","unstructured":"COCONEL Group. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect Dis. 2020;20(7):769\u201370.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-021-01594-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-021-01594-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-021-01594-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T22:46:38Z","timestamp":1627771598000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-021-01594-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1186\/s12911-021-01594-8","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants provided written informed consent before participation. ComPaRe was approved by the Institutional Review Board of H\u00f4tel-Dieu Hospital, Paris (IRB: 0008367).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript contains no details, images, or videos relating to an individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests and no financial associations that may be relevant or seen as relevant to the submitted manuscript. The authors have no association with commercial entities that could be viewed as having an interest in the general area of the submitted manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}